Independent research on the U.S. markets, Baptista Research

Baptista Research

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. 

We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Eli Lilly is once again signalling how aggressively it intends to deploy the cash flows generated by its obesity and diabetes franchises into higher-value pipeline assets, and Kelonia Therapeutics has emerged as a notable example of that strategy.</li><li>The reported transaction structure, with $3.25 billion upfront and the potential to reach $7 billion if development, regulatory, and commercial milestones are achieved, highlights how highly Lilly appears to value platform optionality in oncology rather than near-term revenue contribution.</li><li>Kelonia is developing an early-stage multiple myeloma therapy built on a next-generation CAR-T approach that aims to bypass some of the most burdensome features of conventional cell therapy, including chemotherapy preconditioning and complex individualized manufacturing.</li></ul>

Eli Lilly is once again signalling how aggressively it intends to deploy the cash flows generated by its obesity and diabetes franchises into higher-value pipeline assets, and Kelonia Therapeutics has emerged as a notable example of that strategy.The reported transaction structure, with $3.25 billion upfront and the potential to reach $7 billion if development, regulatory, and commercial milestones are achieved, highlights how highly Lilly appears to value platform optionality in oncology rather than near-term revenue contribution.Kelonia is developing an early-stage multiple myeloma therapy built on a next-generation CAR-T approach that aims to bypass some of the most burdensome features of conventional cell therapy, including chemotherapy preconditioning and complex individualized manufacturing.

Eli Lilly Acquisition Shock: $7 Billion Bet That Could Redefine Cancer Treatment!

Eli Lilly & Co

Eli Lilly Acquisition Shock: $7 Billion Bet That Could Redefine Cancer Treatment!